Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
REDWOOD CITY, Calif., April 24, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2018 financial results will be released after market close on Thursday, May 10, 2018. Starting at 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.
After releasing first quarter 2018 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com.
Conference Call Information
When: Thursday, May 10, 2018 at 4:30 p.m. ET
Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)
Conference ID: 2767588
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
